Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2010

View Archived Issues

Phase IIa data disclosed on tideglusib in Alzheimer's disease

Novartis reviews second quarter of 2010

EVP-0015962 improves cognitive deficit in mouse model of Alzheimer's disease

PDIP-38 is a candidate biomarker for progression of HPV-16-associated cervical dysplasia

Insulin degludec improves glucemic control in phase II trials in type 1 and 2 diabetes

Drug-targetable rearrangements of RAF kinase pathway members identified in prostate cancer

Repros Therapeutics to start low-dose study of Proellex

Tarsa advances phase III oral calcitonin trial in postmenopausal osteoporosis

Enrollment begins in phase II MM-121 trial in breast cancer

NACI updates recommendations on rotavirus vaccination in Canada

University of Michigan claims new STAT-3 inhibitors

AiCuris discloses new anti-HIV agents

Algeta concludes manufacture and supply agreements for alpharadin

S/GSK-1265744 is active against RAL-resistant HIV isolates in vitro

Fresenius Medical Care expands its dialysis products business

FDA grants CBLB-502 fast track status for acute radiation syndrome

DSMB recommends completion of phase II FV-100 trial in shingles

NPS Pharma advances phase III trial of teduglutide in short bowel syndrome

ConjuChem Biotechnologies files for bankruptcy

CP-404 successfully completes pilot phase I study for obesity

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

Euthymics Bioscience acquires DOV Pharma and continues EB-1010 development

MDRNA shareholders approve Cequent acquisition and name change to Marina Biotech

Korean scientists discover new cyclic penta-depsipeptides

Sirtris Pharmaceuticals describes new SIRT modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...